Skip to main content
Full access
Letter
Published Online: 1 November 2004

Ejaculation After Defecation Without Orgasm Induced by Milnacipran

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
SIR: Milnacipran is a novel serotonin (5-hydroxytryptamine [5-HT]) and noradrenaline reuptake inhibitor (SNRI). To our knowledge, this is the first report of a depressive patient who experienced ejaculation after defecation without orgasm in the treatment of milnacipran.

Case Report

Mr. A was a 31-year-old man. He had no past and familial history of psychiatric and urologic disorders. He got depressed and started to have milnacipran of 50 mg/day. One week later, the daily dosage of milnacipran was increased to 100 mg. Four weeks after the beginning of milnacipran, he first experienced ejaculation after defecation without orgasm. As he felt ashamed of having such a symptom, he did not report it to the doctor. Seven weeks after the beginning of milnacipran, his depressive symptoms remitted. At that time he reported his ejaculation after defecation to the doctor. He wished to keep on having milnacipran in spite of that symptom, because he was afraid of a recurrence of depression. Milnacipran was prescribed thereafter. He continued to experience ejaculation after defecation about once per 2 or 3 weeks. Additionally, he occasionally observed emission of sperm at the end of micturition. One year after his first visit to our hospital, milnacipran was gradually decreased and stopped. He no longer experienced ejaculation after defecation. He started his new sexual life about 3 months after the cessation of milnacipran. He had no sexual dysfunction.

Comments

He had no intercourse for about 6 months before the beginning and for about 3 months after the cessation of milnacipran; nevertheless he did not experience ejaculation after defecation and emission of sperm at the end of micturition during those periods. This course shows that involuntary ejaculation was caused by the medication of milnacipran, not by the overpooling of sperm.
5-HT acts inhibitory on seminal ejaculation in the brain.1 The sexual side effects most frequently observed in selective 5-HT reuptake inhibitors (SSRIs) are delayed ejaculation and absent or delayed orgasm.2 5-HT increased by SSRIs is supposed to cause these side effects by its central effect. On the other hand, peripherally, seminal emission and ejaculation are primarly under adrenergic control.3 There have been two case reports about spontaneous ejaculation induced by reboxetine.4,5 Reboxetine is a selective noradrenaline reuptake inhibitor, and noradrenaline increased by reboxetine is supposed to cause spontaneous ejaculation by its peripheral effect. Though venlafaxine, one of SNRIs, showed ejaculation dysfunction in the frequency of 12% in a study of 1,033 patients, milnacipran was not reported to show ejaculation disturbance in a study of 1,867 patients.6 It might be due to well-balanced inhibitory effect of milnacipran on the reuptake of 5-HT and noradrenaline. However, this case suggests that milnacipran also has a possibility to induce ejaculation dysfunction. Patients generally hesitate to talk about their sexual problems with the doctor; therefore, this kind of side effects can be underestimated. We should be careful about the sexual dysfunction induced by milnacipran.

References

1.
McIntosh TK, Barfield RJ: Brain monoaminergic control of male reproductive behavior, I: serotonin and the post-ejaculatory refractory period. Behav Brain Res 1984; 12:255–265
2.
Rosen RC, Lane RM, Menza M: Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol 1999; 19:67–85
3.
Gutierrez MA, Stimmel GL: Management of and counseling for psychotropic drug-induced sexual dysfunction. Pharmacotherapy 1999; 19:823–831
4.
Haberfellner EM: Sexual dysfunction caused by reboxetine. Pharmacopsychiatry 2002; 35:77–78
5.
O’Flynn R, Michael A: Reboxetine-induced spontaneous ejaculation. Br J Psychiatry 2000; 177:567–568
6.
Briley M: Specific serotonin and noradrenaline reuptake inhibitors (SNRIs): a review of their pharmacology, clinical efficacy and tolerability. Hum Psychopharmacol 1998; 13:99–111

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: 544
PubMed: 15616184

History

Published online: 1 November 2004
Published in print: November 2004

Authors

Affiliations

Keizo Yoshida, M.D., Ph.D.
Hisashi Higuchi, M.D., Ph.D.
Hitoshi Takahashi, M.D., Ph.D.
Tetsuo Shimizu, M.D., Ph.D.
Department of Psychiatry, Akita University School of Medicine, Akita, Japan

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share